The purpose of this study is to evaluate the effect of ARO-AAT Injection (also referred to as ARO-AAT) on a histological liver disease activity scale in participants with AAT-associated liver disease over time. Participants will receive multiple subcutaneous doses of ARO-AAT.

• Inclusion Criteria :
  • Diagnosis of AATD
  • Women of childbearing potential must have a negative pregnancy test, cannot be breast feeding, and must be willing to use contraception
  • Willing to provide written informed consent and to comply with study requirements
  • Non-smoker for at least 1 year
  • No abnormal finding of clinical relevance at screening
• Exclusion Criteria :
  • Clinically significant health concerns other than AATD
  • Previous diagnosis or diagnosis at Screening of definitive liver cirrhosis
  • Regular use of alcohol within one month prior to Screening
  • Use of an investigational agent or device within 30 days prior to dosing or current participation in an investigational study involving therapeutic intervention
  • Use of illicit drugs within 1 year prior to Screening
• Study start date : 15/11/2019
• Study end date : 15/11/2021
• Wales-Based Study Contact : please speak to your clinician
• Principal Investigator : Alice Turner

Contact details

England- Birmingham/Cambridge Scotland- EdinburghEngland Anita.Pye@uhb.nhs.uk clinicaltrials.gov